Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda

Neurology

Volumn 72, Issue 2, 2009, Pages 165-170

  Sacktor, N ^a,f   Nakasujja, N ^b   Skolasky, R L ^a   Robertson, K ^c   Musisi, S ^b   Ronald, A ^d   Katabira, E ^b   Clifford, D B ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TRIOMMUNE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DEMENTIA; DEMOGRAPHY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROLOGICAL COMPLICATION; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSORY NEUROPATHY; SEX DIFFERENCE; SPEECH ARTICULATION; THINKING; TREATMENT DURATION; TREATMENT OUTCOME; UGANDA; VERBAL MEMORY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DEVELOPING COUNTRY; DISABILITY; METHODOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; DEVELOPING COUNTRIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); RISK ASSESSMENT; STAVUDINE; TREATMENT OUTCOME; UGANDA;

EID: 60549083974     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000339042.96109.86     Document Type: Article

References (21)

1. Joint United Nations Program on HIV/AIDS. UNAIDS and the World Health Organization. Report on AIDS Epidemic Update, 2006. 10th Anniversary ed. 2006.
2. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 (suppl 2):115-121.
3. Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002;58:1764-1768.
4. de la Monte SM, Gabuzda DH, Ho DD, et al. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 1988;23:485-492.
5. So YT, Holtzman DM, Abrams DI, et al. Peripheral neuropathy associated with acquired immunodeficiency syndrome: prevalence and clinical features from a population-based survey. Arch Neurol 1988;45:945-948.
6. Wong M, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007;68:350-355.
7. Sacktor NC, Skolasky RL, Lyles RH, et al. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol 2000;6: 84-88.
8. Sacktor NC, Lyles RH, Skolasky RL, et al. Combination antiretroviral therapy including protease inhibitors improves HIV-associated cognitive impairment. Neurology 1999;52:1640-1647.
9. Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004;36:562-566.
10. Sacktor N, Nakasujja N, Skolasky R, et al. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 2006;67:311-314.
11. Martin C, Solders G, Sonnerborg A, et al. Antiretroviral therapy may improve sensory function in HIV-infected patients: apilot study. Neurology 2000;54:2120-2127.
12. Quinn TC. The Academic Alliance for AIDS Care and Prevention in Africa. Hopkins HIV Rep 2001;13:1-4.
13. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-1374.
14. Karnofsky DA, Abelman WH, Craver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-656.
15. Maj M, Satz P, Janssen R, et al. WHO Neuropsychiatric AIDS Study, cross-sectional phase II: neuropsychological and neurological findings. Arch Gen Psychiatry 1994;51: 51-61.
16. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Service; 1982.
17. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079-1083.
18. Fitzmaurice GM, Laird NM. Generalized linear mixture models for handling nonignorable dropouts in longitudinal studies. Biostatistics 2000;1:141-156.
19. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-1060.
20. Peters K, Nakasujja N, Robertson KR, et al. Development of peripheral neuropathy after stavudine-based antiretroviral therapy in HIV positive (HIV+) patients in sub-Saharan Africa. Presented at: 132nd Annual Meeting of the American Neurological Association; October 7, 2007; Washington, DC; 2007.
21. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.